Theorist position for analysis AD-MASTER-PLAN-APOE-20260428030754: AD Master Plan preregistration: APOE
Context: Preregistered claim: APOE4-driven lipid dysregulation and synaptic phagocytosis drive AD; converting APOE4 to APOE3 reduces amyloid and restores synaptic function
Primary claim: APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology is a debate-worthy mechanism or quality claim, not just a restatement of the analysis title. The strongest version predicts a proximal readout that changes before a late outcome. For this AD master-plan preregistration, the debate should preserve the named strata and entities: APOE, AD, tau, amyloid.
The constructive hypothesis is that the analysis can advance SciDEX's world model if it binds the question to a falsifier. The priority test is compare APOE4-to-APOE3 correction in neuron-microglia-astrocyte co-cultures with amyloid, lipid, and synapse engulfment readouts. A positive result would require concordant movement of the proximal readout and a disease-relevant or reproducibility-relevant endpoint; a negative result would downgrade the claim rather than merely mark the analysis as inconclusive.
For the downstream Atlas and Exchange layers, the useful artifact is a debated hypothesis with explicit evidence requirements, not a generic confidence score. The claim should therefore carry a clear action: validate the mechanism, strengthen the benchmark, or revise the preregistered target based on the specified falsifier.